PMID- 31372837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2193-8229 (Print)
IS  - 2193-6382 (Electronic)
IS  - 2193-6382 (Linking)
VI  - 8
IP  - 3
DP  - 2019 Sep
TI  - Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) 
      Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled 
      Trials.
PG  - 445-452
LID - 10.1007/s40121-019-0255-0 [doi]
AB  - INTRODUCTION: The efficacy and safety of telavancin versus vancomycin in 
      microbiologically evaluable patients with hospital-acquired or 
      ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with 
      vancomycin minimum inhibitory concentration (MIC) >/= 1.0 microg/mL was analyzed using 
      data derived from previously reported Assessment of Telavancin for Treatment of 
      Hospital-Acquired Pneumonia (ATTAIN) trials. METHODS: This post hoc subgroup 
      analysis of two randomized, double-blind, comparator-controlled, parallel-group 
      phase 3 trials conducted at 274 sites in 38 countries included 194 
      microbiologically evaluable patients with HAP/VAP caused by monomicrobial S. 
      aureus with vancomycin MIC >/= 1.0 microg/mL. Patients received intravenous telavancin 
      (10 mg/kg every 24 h) or intravenous vancomycin (1 g every 12 h with 
      site-specific modifications) for 7-21 days. Efficacy was assessed by clinical 
      cure, defined as improvement or non-progression of radiographic findings at end 
      of treatment and resolution of pneumonia signs and symptoms at 
      follow-up/test-of-cure visits, and survival 28 days post-randomization. Safety 
      was assessed from categorical shifts in creatinine clearance during therapy and 
      adverse events (AEs). RESULTS: Clinical cure rates were numerically greater 
      following telavancin versus vancomycin treatment overall (85.4% vs. 74.3%; 
      treatment difference [95% confidence interval (CI)], 11.1% [- 0.002%, 22.2%]) and 
      in patients aged >/= 65 years (81.6% vs. 66.2%; treatment difference [95% CI], 
      15.5% [- 0.9%, 30.2%]) patients with VAP (92.3% vs. 47.6%; treatment difference 
      [95% CI], 44.7% [18.1%, 64.9%]), and patients with baseline Acute Physiology And 
      Chronic Health Evaluation II score >/= 20 (71.4% vs. 55.6%; treatment difference 
      [95% CI], 15.9% [- 11.7%, 40.5%]). Renal function declined in 7 (7.9%) patients 
      receiving telavancin and 6 (5.7%) patients receiving vancomycin. Survival 
      proportion was numerically higher (85.2% vs. 80.2%; treatment difference [95% 
      CI], 5.0% [- 5.8%, 15.8%]) and AEs were comparable in patients treated with 
      telavancin versus vancomycin. CONCLUSION: Telavancin is an alternative to 
      vancomycin for HAP/VAP caused by S. aureus with vancomycin MIC >/= 1 microg/mL. 
      FUNDING: Theravance Biopharma R&D, Inc., South San Francisco, CA, USA.
FAU - Niederman, Michael S
AU  - Niederman MS
AD  - Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New 
      York, NY, USA.
FAU - Lee, Patrick C
AU  - Lee PC
AD  - Department of Surgery, Baystate Medical Center, Springfield, MA, USA.
FAU - Barriere, Steven L
AU  - Barriere SL
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA.
FAU - Barnes, Chris N
AU  - Barnes CN
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA. 
      cbarnes@sprucebiosicences.com.
FAU - Castaneda-Ruiz, Bibiana
AU  - Castaneda-Ruiz B
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20190801
PL  - New Zealand
TA  - Infect Dis Ther
JT  - Infectious diseases and therapy
JID - 101634499
PMC - PMC6702499
OTO - NOTNLM
OT  - Hospital-acquired pneumonia
OT  - MRSA
OT  - Staphylococcus aureus
OT  - Telavancin
OT  - Vancomycin
OT  - Ventilator-associated pneumonia
EDAT- 2019/08/03 06:00
MHDA- 2019/08/03 06:01
PMCR- 2019/08/01
CRDT- 2019/08/03 06:00
PHST- 2019/04/18 00:00 [received]
PHST- 2019/08/03 06:00 [pubmed]
PHST- 2019/08/03 06:01 [medline]
PHST- 2019/08/03 06:00 [entrez]
PHST- 2019/08/01 00:00 [pmc-release]
AID - 10.1007/s40121-019-0255-0 [pii]
AID - 255 [pii]
AID - 10.1007/s40121-019-0255-0 [doi]
PST - ppublish
SO  - Infect Dis Ther. 2019 Sep;8(3):445-452. doi: 10.1007/s40121-019-0255-0. Epub 2019 
      Aug 1.